CA3138168A1 - Fused heterocyclic derivatives - Google Patents

Fused heterocyclic derivatives Download PDF

Info

Publication number
CA3138168A1
CA3138168A1 CA3138168A CA3138168A CA3138168A1 CA 3138168 A1 CA3138168 A1 CA 3138168A1 CA 3138168 A CA3138168 A CA 3138168A CA 3138168 A CA3138168 A CA 3138168A CA 3138168 A1 CA3138168 A1 CA 3138168A1
Authority
CA
Canada
Prior art keywords
compound
formula
membered monocyclic
hbv
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3138168A
Other languages
English (en)
French (fr)
Inventor
Sandrine Celine Grosse
Lindsey Graham DERATT
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
Serge Maria Aloysius Pieters
Bart Rudolf Romanie Kesteleyn
Wim Gaston Verschueren
Jan Martin Berke
Morgan Charles R. LECOMTE
Carolina Martinez Lamenca
Tim Hugo Maria Jonckers
Gang Deng
Yimin Jiang
Yanping Xu
Zhanling CHENG
Lili Hu
Scott D. Kuduk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
Original Assignee
Janssen Sciences Ireland ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71741889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3138168(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Sciences Ireland ULC filed Critical Janssen Sciences Ireland ULC
Publication of CA3138168A1 publication Critical patent/CA3138168A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3138168A 2019-05-28 2020-05-27 Fused heterocyclic derivatives Pending CA3138168A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962853533P 2019-05-28 2019-05-28
EP19176933.0 2019-05-28
US62/853,533 2019-05-28
EP19176933 2019-05-28
CNPCT/CN2020/085720 2020-04-20
CN2020085720 2020-04-20
PCT/US2020/034643 WO2020243135A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Publications (1)

Publication Number Publication Date
CA3138168A1 true CA3138168A1 (en) 2020-12-03

Family

ID=71741889

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3138168A Pending CA3138168A1 (en) 2019-05-28 2020-05-27 Fused heterocyclic derivatives

Country Status (19)

Country Link
EP (1) EP3976617B1 (https=)
JP (1) JP2022535734A (https=)
KR (1) KR20220012913A (https=)
CN (1) CN113906028A (https=)
AU (1) AU2020285718A1 (https=)
BR (1) BR112021022889A8 (https=)
CA (1) CA3138168A1 (https=)
CL (1) CL2021003155A1 (https=)
CO (1) CO2021016433A2 (https=)
CR (1) CR20210666A (https=)
DO (1) DOP2021000230A (https=)
IL (1) IL288322A (https=)
JO (1) JOP20210313A1 (https=)
MA (1) MA56043A (https=)
MX (1) MX2021014575A (https=)
PE (1) PE20220767A1 (https=)
PH (1) PH12021552974A1 (https=)
SG (1) SG11202113167QA (https=)
WO (1) WO2020243135A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744927A (zh) * 2020-12-02 2023-09-12 杨森科学爱尔兰无限公司 稠合杂环衍生物及其在治疗hbv感染中的用途
WO2022116999A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives and their use in the treatment of hbv infection
WO2022116998A1 (en) * 2020-12-02 2022-06-09 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives as hbv inhibitors
WO2022253255A1 (en) * 2021-06-02 2022-12-08 Janssen Sciences Ireland Unlimited Company Fused heterocyclic derivatives
CN117715909A (zh) 2021-06-02 2024-03-15 杨森科学爱尔兰无限公司 稠合杂环衍生物
WO2024114709A1 (en) * 2022-12-01 2024-06-06 Janssen Sciences Ireland Unlimited Company A crystal form of a fused heterocycle derivative compound
WO2024140851A1 (zh) * 2022-12-28 2024-07-04 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2993174A1 (en) * 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridine derivatives and their use in therapy
RU2742305C2 (ru) * 2014-12-30 2021-02-04 Новира Терапьютикс, Инк. Производные и способы лечения инфекций гепатита в
AU2017290755B2 (en) * 2016-06-29 2021-07-01 Novira Therapeutics, Inc. Diazepinone derivatives and their use in the treatment of hepatitis B infections
JP6935434B2 (ja) * 2016-06-29 2021-09-15 ノヴィラ・セラピューティクス・インコーポレイテッド オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用
SG11202111236UA (en) * 2019-04-30 2021-11-29 Aicuris Gmbh & Co Kg Novel indole-2-carboxamides active against the hepatitis b virus (hbv)

Also Published As

Publication number Publication date
WO2020243135A1 (en) 2020-12-03
EP3976617B1 (en) 2025-04-23
BR112021022889A2 (pt) 2022-01-04
PE20220767A1 (es) 2022-05-16
CR20210666A (es) 2022-03-11
PH12021552974A1 (en) 2022-07-11
DOP2021000230A (es) 2022-05-31
EP3976617A1 (en) 2022-04-06
CO2021016433A2 (es) 2021-12-10
BR112021022889A8 (pt) 2024-03-05
CL2021003155A1 (es) 2022-07-22
JP2022535734A (ja) 2022-08-10
MA56043A (fr) 2022-04-06
MX2021014575A (es) 2022-05-24
CN113906028A (zh) 2022-01-07
JOP20210313A1 (ar) 2021-11-25
SG11202113167QA (en) 2021-12-30
AU2020285718A1 (en) 2022-02-03
IL288322A (en) 2022-01-01
KR20220012913A (ko) 2022-02-04

Similar Documents

Publication Publication Date Title
CA3138168A1 (en) Fused heterocyclic derivatives
CA2881322A1 (en) 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
KR20210139319A (ko) Hbv 감염 또는 hbv-유도성 질환의 치료에 사용하기 위한 융합 고리 피리미돈 유도체
US20230076319A1 (en) Inhibitors of hepatitis b virus
US20240279227A1 (en) Fused heterocyclic derivatives
US20220348592A1 (en) Fused heterocyclic derivatives
CA3136493A1 (en) Diazepinone derivatives as capsid assembly modulators
WO2020239864A1 (en) Fused heterocycle derivatives as capsid assembly modulators
CA3138163A1 (en) Fused heterocyclic derivatives as antiviral agents
CA3137676A1 (en) Fused heterocyclic derivatives
EA047929B1 (ru) Сочлененные гетероциклические производные
CA3218156A1 (en) Fused heterocyclic derivatives
HK40066700A (zh) 稠合杂环衍生物
CA3138149A1 (en) Azepines as hbv capsid assembly modulators
WO2022116998A1 (en) Fused heterocyclic derivatives as hbv inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240513

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241218

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241225

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241225

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241225

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250529

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250929